Complete enrollment in the pivotal ADVANCE-2 study for pimavanserin
Delivered after the deadline (215 days after the deadline)
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 28 Feb 2022
- Due
- 31 Dec 2022
- Delivered
- 3 Aug 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“complete enrollment in our pivotal ADVANCE-2 study for pimavanserin for the negative symptoms of schizophrenia”
What we found
Evidence strength A What the grades mean
The company failed to complete enrollment in the ADVANCE-2 study by the end of 2022, later updating the timeline to mid-2023 and confirming completion in an August 2023 filing.
-
A Acadia Pharmaceuticals Inc. 8-K filed 2023-02-28
“Enrollment is expected to be completed for ADVANCE-2, a Phase 3 study evaluating pimavanserin for the negative symptoms of schizophrenia, around mid-year 2023.” ✓ confirmed on the page
-
A Acadia Pharmaceuticals Inc. 10-Q filed 2023-08-03
“We completed enrollment in ADVANCE-2 and expect that top-line results will be available in the first quarter of 2024.” ✓ confirmed on the page
Market reaction: the shares moved +4.6% against the S&P 500 over the three sessions around the disclosure (27 Feb 2023 to 2 Mar 2023). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +181 days
- 2 versions
-
Version 1 · original · stated 28 Feb 2022
Deadline 31 Dec 2022 (“this year”)
-
Version 2 · stated 28 Feb 2023
Deadline 30 Jun 2023 (“around mid-year 2023”) · wording expected
“Enrollment is expected to be completed for ADVANCE-2, a Phase 3 study evaluating pimavanserin for the negative symptoms of schizophrenia, around mid-year 2023.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Complete
- Deliverable
- Enrollment in ADVANCE-2 study
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Acadia Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-ACAD-002576 · Corrections policy